OBG SCIENTIFIC DIVISION LIMITED
Get an alert when OBG SCIENTIFIC DIVISION LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2026-09-06 (in 4mo)
Last made up 2025-08-23
Watchouts
None on the register
Cash
£6
0% vs 2023
Net assets
£6
+100% first positive since 2023
Employees
0
Average over period
Profit before tax
£450K
+250% highest in 5 filed years
Net assets
6-year trend · vs Industrials median
Accounts
6-year trend · latest reflected 2024-12-31
| Metric | Trend | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Turnover | — | — | — | — | — | — | |
| Operating profit | — | — | — | — | -£300,001 | — | |
| Profit before tax | — | £0 | £300,000 | £0 | -£300,001 | £450,001 | |
| Net profit | — | £0 | — | £0 | -£300,001 | £450,001 | |
| Cash | — | £6 | £6 | £6 | £6 | £6 | |
| Total assets less current liabilities | — | £6 | £40,006 | £40,006 | -£259,995 | £6 | |
| Net assets | — | — | — | — | -£259,995 | £6 | |
| Equity | £6 | £6 | £40,006 | £40,006 | -£259,995 | £6 | |
| Average employees | — | 0 | 0 | 0 | 0 | 0 | |
| Wages | — | — | — | — | — | — | |
| Directors' remuneration | — | — | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
0%
£6 £6
-
Net assets
+100%
-£259,995 £6
-
Employees
—
Not reported
-
Profit before tax
+250%
-£300,001 £450,001
highest in 5 filed years
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Return on capital employed | — | — | — | — | 115.4% | — | |
| Gearing (liabilities / total assets) | — | — | — | — | 25740.5% | 100.0% | |
| Current ratio | — | — | — | — | 0.00x | 1.00x |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- DSG Audit
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The company has net current liabilities and is dependent on the continued support of its fellow group companies to meet its financial obligations. Directors consider it appropriate to prepare these financial statements on a going concern basis, based on group forecasts and banking facilities.”
Group structure
- OBG SCIENTIFIC DIVISION LIMITED · parent
- Ayrton Saunders Limited 100%
- JM Loveridge Limited 100%
- Pharmaserve (North West) Development Company Limited 100%
- Pharmaserve (North West) Limited 100%
- Ayrton Saunders (Development) Ltd 100%
- Ayrton Saunders Inhalation Ltd 100%
- Ayrton Saunders (Ireland) Ltd 100%
- Ayrton Saunders, Inc. 100%
- OBG Consumer Reg Scientific Ltd 100%
- OBG Consumer Scientifc Ltd 100%
- Nicovations New Zealand Ltd 100%
Significant events
- “Ayrton Saunders, Inc. Dissolved during the year”
- “Pharmaserve (North West) Limited In administration”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 3 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| DIDLICK, Philip James | Director | 2016-02-04 | Jun 1976 | British |
| O'BRIEN, Gerald Francis | Director | 2016-02-04 | Jan 1949 | British |
| O'BRIEN, Padraic Marc | Director | 2016-02-04 | Jun 1979 | British |
Show 3 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BROMILEY, Mark | Secretary | 2021-07-02 | 2025-03-07 |
| DIDLICK, Philip | Secretary | 2016-02-04 | 2021-07-02 |
| BROMILEY, Mark | Director | 2021-11-02 | 2025-03-07 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Obg Pharmaceuticals Ltd | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2024-01-12 | Active |
| Mr Gerald Francis O'Brien | Individual | Significant influence, significant-influence-or-control-as-firm | 2016-04-06 | Ceased 2024-01-12 |
| Mrs Bridget Christina O'Brien | Individual | Significant influence, significant-influence-or-control-as-firm | 2016-04-06 | Ceased 2024-01-12 |
Filing timeline
Last 20 of 55 total filings
Material constitutional events — rename, articles re-file, resolution
- 2023-04-25 MA Memorandum articles
- 2023-04-25 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2025-09-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-08-14 | AA | accounts | Accounts with accounts type full | |
| 2025-03-11 | TM01 | officers | Termination director company with name termination date | |
| 2025-03-11 | TM02 | officers | Termination secretary company with name termination date | |
| 2024-09-30 | AA | accounts | Accounts with accounts type full | |
| 2024-09-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-02-13 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-02-13 | PSC07 | persons-with-significant-control | Cessation of a person with significant control | |
| 2024-02-13 | PSC02 | persons-with-significant-control | Notification of a person with significant control | |
| 2023-11-20 | MR04 | mortgage | Mortgage satisfy charge full | |
| 2023-09-29 | AA | accounts | Accounts with accounts type full | |
| 2023-09-21 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2023-05-04 | SH01 | capital | Capital allotment shares | |
| 2023-04-25 | MA | incorporation | Memorandum articles | |
| 2023-04-25 | RESOLUTIONS | resolution | Resolution | |
| 2023-04-25 | SH10 | capital | Capital variation of rights attached to shares | |
| 2023-04-25 | SH08 | capital | Capital name of class of shares | |
| 2023-01-19 | RP04CS01 | confirmation-statement | Second filing of confirmation statement with made up date | |
| 2022-10-26 | CS01 | confirmation-statement | Confirmation statement | |
| 2022-10-21 | SH03 | capital | Capital return purchase own shares treasury capital date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.